Age, yr, median [IQR]
|
44 [36.5–63.5]
|
Female sex (%)
|
15 (100.0 %)
|
Disease duration, yr, median [IQR]
|
1 [0.5–6.5]
|
Whole unstimulated salivary flow (<0.1 ml/min)
|
12 (80 %)
|
Schirmer’s test ≤5 mm
|
10 (66.7 %)
|
Focus score ≥1
|
12 (80 %)
|
Baseline focus score, median [IQR]
|
1.6 [1–2.4]
|
Anti-SSA antibodies
|
14 (93.3 %)
|
Anti-SSB antibodies
|
10 (66.7 %)
|
Current background medication
| |
Corticosteroids
|
4 (26.7 %)
|
Hydroxychloroquine
|
5 (33.3 %)
|
Methotrexate
|
0 (0 %)
|
Reason for inclusion
| |
Systemic complications
|
11 (73.3 %)
|
Recent-onset disease
|
4 (26.7 %)
|
Increase in B-cell biomarker values
|
11 (73.3 %)
|
ESSDAI score (0–123), median [IQR]
|
7 [3–11]
|
ESSPRI score (0–10), median [IQR]
|
6.33 [6–7.33]
|